关于 Khan 等人 2021 年文献报告和解释存在的问题。
Issues with reporting and interpretation of Khan et al. 2021.
机构信息
Nuffield Department of Primary Care Health Sciences, University of Oxford, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG, England.
出版信息
BMC Infect Dis. 2022 Jun 22;22(1):567. doi: 10.1186/s12879-022-07551-8.
Abstract
A recent publication in BMC Infectious Diseases concerning the use of convalescent plasma for the treatment of COVID-19 had a number of major issues. This correspondence details specific instances of unclear reporting as well as major omissions when discussing the context of the trial. These render the study's findings and conclusions misleading.
摘要
最近发表在《BMC 传染病》杂志上的一篇关于使用恢复期血浆治疗 COVID-19 的文章存在一些重大问题。本通信详细说明了在报告方面不明确的具体情况，以及在讨论试验背景时的重大遗漏。这些问题使得研究的发现和结论具有误导性。
相似文献
1
Issues with reporting and interpretation of Khan et al. 2021.关于 Khan 等人 2021 年文献报告和解释存在的问题。
BMC Infect Dis. 2022 Jun 22;22(1):567. doi: 10.1186/s12879-022-07551-8.
2
Correspondence on 'CONVALESCENT plasma for COVID-19'.关于“COVID-19康复期血浆治疗”的通信
Eur J Clin Invest. 2021 Nov;51(11):e13677. doi: 10.1111/eci.13677. Epub 2021 Sep 13.
3
Convalescent plasma to treat COVID-19: clinical experience and efficacy.恢复期血浆治疗 COVID-19：临床经验和疗效。
Aging (Albany NY). 2021 Mar 18;13(6):7758-7766. doi: 10.18632/aging.202795.
4
Convalescent plasma therapy: A passive therapy for an aggressive COVID-19.恢复期血浆疗法：一种针对侵袭性新冠病毒病的被动疗法。
J Med Virol. 2020 Nov;92(11):2251-2253. doi: 10.1002/jmv.26047. Epub 2020 Jun 9.
5
Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.恢复期血浆/甲磺酸卡莫司他用于早期SARS-CoV-2 Q-PCR阳性高危个体（RES-Q-HR）：一项随机对照试验研究方案的结构化总结
Trials. 2021 May 17;22(1):343. doi: 10.1186/s13063-021-05181-0.
6
Heterogeneity in COVID-19 Convalescent Plasma Clinical Trials.新冠康复期血浆临床试验中的异质性
Clin Pharmacol Ther. 2022 May;111(5):995-1000. doi: 10.1002/cpt.2281. Epub 2021 Jun 17.
7
Convalescent plasma for COVID-19 considerations.关于新冠病毒病恢复期血浆的考量
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
8
Convalescent plasma transfusion for the treatment of COVID-19: Systematic review.恢复期血浆输注治疗 COVID-19：系统评价。
J Med Virol. 2020 Sep;92(9):1475-1483. doi: 10.1002/jmv.25961. Epub 2020 May 12.
9
Convalescent Plasma: A Potential Life-Saving Therapy for Coronavirus Disease 2019 (COVID-19).康复期血浆：一种治疗2019冠状病毒病（COVID-19）的潜在救命疗法。
Front Public Health. 2020 Aug 6;8:437. doi: 10.3389/fpubh.2020.00437. eCollection 2020.
10
Randomized clinical trial to evaluate safety and efficacy of convalescent plasma use among hospitalized patients with COVID-19 (PERUCONPLASMA): a structured summary of a study protocol for a randomized controlled trial.随机临床试验评估 COVID-19 住院患者使用恢复期血浆的安全性和疗效（PERUCONPLASMA）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 May 17;22(1):342. doi: 10.1186/s13063-021-05189-6.
本文引用的文献
1
Citation bias: questionable research practice or scientific misconduct?引用偏差：是有问题的研究行为还是科学不端行为？
J R Soc Med. 2022 Jan;115(1):31-35. doi: 10.1177/01410768221075881.
2
Usefulness of convalescent plasma transfusion for the treatment of severely ill COVID-19 patients in Pakistan.恢复期血浆输注治疗巴基斯坦重症 COVID-19 患者的效果。
BMC Infect Dis. 2021 Sep 27;21(1):1014. doi: 10.1186/s12879-021-06451-7.
3
Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.恢复期血浆或高免疫球蛋白用于 COVID-19 患者：一项实时系统评价。
Cochrane Database Syst Rev. 2021 May 20;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub4.
4
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.COVID-19 患者住院期间的恢复期血浆治疗（RECOVERY）：一项随机对照、开放标签、平台试验。
Lancet. 2021 May 29;397(10289):2049-2059. doi: 10.1016/S0140-6736(21)00897-7. Epub 2021 May 14.
5
Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.恢复期血浆治疗与 COVID-19 患者临床结局的关联：系统评价和荟萃分析。
JAMA. 2021 Mar 23;325(12):1185-1195. doi: 10.1001/jama.2021.2747.
6
Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study.恢复期血浆治疗重症 COVID-19：一项倾向评分匹配对照研究。
Nat Med. 2020 Nov;26(11):1708-1713. doi: 10.1038/s41591-020-1088-9. Epub 2020 Sep 15.
7
CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials.CONSORT 2010解释与详述：平行组随机试验报告的更新指南
BMJ. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869.
Zotero 插件